La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases SAN DIEGO, Calif. and WATERTOWN, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outc
June 24, 2020
· 14 min read